Logo-npj
Submitted: 24 May 2021
Accepted: 02 Sep 2021
ePublished: 12 Sep 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2022;11(1): e11.
doi: 10.34172/npj.2022.11

Scopus ID: 85119614481
  Abstract View: 8016
  PDF Download: 3182

Original

Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy

Foroogh Sabzghabaei 1 ORCID logo, Afsaneh Sedighi 2* ORCID logo, Raziyeh Shahi 2 ORCID logo, Vahid Mahmoodi 2 ORCID logo, Jahanbakhsh Khamseh 2 ORCID logo, Neda Rahimian 2 ORCID logo

1 Department of Medicine, Firoozabadi Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Department of Internal Medicine, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran
*Corresponding Author: *Corresponding author: Afsaneh Sedighi, Email: Researchcenter199@gmail.com, , Email: researchcenter199@gmail.com

Abstract

Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients.

Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy.

Patients and Methods: In this study, 160 HIV patients under tenofovir therapy were enrolled and the prevalence of nephropathy and proximal tubule disorder was determined and compared.

Results: We found, the proximal tubule involvement in 25%, 6.8%, 2.2% and 0% in first year, 2–5 years , 6–10 years and 11–18 years of disease involvement respectively, (P = 0.02). The mean glomerular filtration rate (GFR) diminution was 2.15%, 10.53%, 12.6% and 17.79%, in the first, 2–5, 6–10, and 11–18 years, respectively, again showing a significant difference between years (P = 0.02). Proteinuria was seen in 13.1% of patients.

Conclusion: We concluded that GFR diminution and proximal tubule involvement are common and important to be managed in HIV-positive patients under tenofovir therapy, and discontinuation of drug has no positive effect on GFR.



Implication for health policy/practice/research/medical education:

This study reflects complications related to administration of tenofovir in human immunodeficiency virus (HIV) patients and could serve as a practical guide for HIV specialists in administration of HIV antiviral therapy.

Please cite this paper as: Sabzghabaei F, Sedighi A, Shahi R, Mahmoodi V, Khamseh J, Rahimian N. Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy. J Nephropharmacol. 2022;11(1):e11. DOI: 10.34172/npj.2022.11.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 8017

Your browser does not support the canvas element.


PDF Download: 3182

Your browser does not support the canvas element.